MedTrace Logo

Probiotics Combined With Chemotherapy for Patients With Advanced NSCLC

NCT03642548 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-02-25

No results posted yet for this study

Summary

Based on the theory of intestinal lung axis, the effect of new therapy on patients with advanced NSCLC was observed by adjusting the intestinal micro-ecology and combining existing platinum-based doublet chemotherapy.

Conditions

  • Probiotics Plus Chemotherapy

Interventions

DRUG

bifico

Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.

DRUG

placebo

Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Shanghai Chest Hospital

    collaborator OTHER

  • Shanghai 10th People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-21
Primary Completion
2024-03-01
Completion
2024-03-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642548 on ClinicalTrials.gov